1. CSFB Healthcare Conference
Joe Mahady
Senior Vice President, Wyeth and
President Global Business,
Wyeth Pharmaceuticals
November 13, 2007

2. Forward-Looking Statement
The statements in this presentation that are not historical facts are forward-
looking statements based on current expectations of future events that
involve risks and uncertainties including, without limitation, risks
associated with the inherent uncertainty of pharmaceutical research,
product development, manufacturing, commercialization, economic
conditions including interest and currency exchange rate fluctuations, the
impact of competitive or generic products, product liability and other types
of lawsuits, the impact of legislative and regulatory compliance and
obtaining approvals, and patent, and other risks and uncertainties,
including those detailed from time to time in Wyeth’s periodic reports,
including quarterly reports on Form 10-Q and the annual report on Form 10-
K, filed with the Securities and Exchange Commission. Quarterly results, in
particular, can vary due to issues which include, but are not limited to,
changes in exchange rates, the timing of actions taken by the Company to
ensure long-term improvements to our manufacturing processes, the
timing of regulatory approval of new products and/or facilities and the
timing of promotional programs. Actual results may vary materially from
the forward-looking statements. The Company assumes no obligation to
publicly update any forward-looking statements, whether as a result of new
information, future events or otherwise.
2

3. Wyeth Performance: 3rd Quarter and Nine
Months 2007 - Key Financial Elements*
3Q 2007 YTD 2007
Net Revenue +9% +10%
Gross Margin 73.2% 73.3%
SG&A Expense +8% +4%
R&D Expense +5% +9%
Operating Profit +14% +18%
Tax Rate 29.6% 29.3%
$0.90 $2.74
Diluted Earnings Per Share
+7% +10%
*Adjusted to Exclude Certain Significant Item. See Press Release Issued October 18, 2007
3

4. Marketed Products
Strong Performance For Nine Months 2007
Enbrel +22%
$2.4 B (Amgen) $1.5 B (Wyeth) $3.9 B
Effexor +1%
$2.8 B
Prevnar +29%
$1.9 B
Protonix +5%
$1.4 B
YTD 2007 Pharma
Nutritionals +18%
$1.1 B
Revenue +11%
Alliance Rev.* 0%
$973 M
Zosyn +17%
$845 M
Biotech
Premarin Biotech Now
+0%
$791 M Revenues +26%
Represents 36%
YTD 07
BeneFIX +16%
$304 M
of Total Pharma
BMP-2 $284M +23% Revenues
Rapamune +8%
$265 M
$0 $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500 $4,000 $4,500
(in millions)
* Includes Enbrel, Cordis, Altace 4

5. 2006 Wyeth’s Leadership Positions
#1 Antidepressant
#1 RA & Psoriasis Biologic
#1 Vaccine
#1 HT
#1 I.V. Antibiotic
#1 Hemophilia B
#1 Infant Formula (In Markets Where We Compete)
5

6. Ranked #6 In The World
Countries Where Enbrel is Ranked In the Top Ten In
Terms of Sales
(MAT 2Q07)
Enbrel is Ranked #6 Globally and #4 In Europe
Enbrel is Ranked #1 in Sweden and Norway
Enbrel is Ranked in the Top 10 in:
U.K. Germany
Greece Belgium
Luxembourg Spain
U.S. Finland
Ireland Denmark
Netherlands
Source: C&MI, IMS Midas Global Data MAT 2Q07
6

7. Growth Potential
Reliable Safety and Efficacy Profile
n
4 Over 470,000 Patients Treated Worldwide
4 Over One Million Patient Years Market Experience
>500,000 Biologic-Eligible Patients Not Treated With Biologics in
n
EMEA (All Indications)
>300,000 Biologic-Eligible RA Patients Not Treated With Biologics in
n
Japan
4 Japanese Post Marketing Surveillance Program Lifted 2Q07
Significant Growth Opportunities Exist
n
4 Biologics Market Penetration:
- Ra: U.S. = ~48%; EU = ~41%
- Psoriasis: U.S. = ~16%; EU = ~12%
$3 Billion Enbrel Sales in 2010
(Outside North America)
7

8. Growth Potential
Registered in 89 Countries; Launched in 86 Countries
n
Current and Future Opportunities Birth Cohorts
Current National Immunization Programs ~ 10 Million
(17 Programs to Date)
Announced National Immunization Programs ~ 1 Million
(Ireland, Cyprus, New Zealand, Costa Rica, Peru)
Potential National Immunization Programs (2008-2009) ~ 12 Million
(e.g. Brazil, South Africa, Saudi Arabia ,Czech Republic, Turkey)
Private Markets ~ 38 Million
(India, Indonesia, Pakistan, Philippines, Romania)
Future Markets ~ 20 Million
(China, Japan, Russia)
x
$3 Billion Prevnar Sales in 2010 2009
(Infant Vaccination)
8

9. Prevnar 13v – Expanding the Coverage
Infant Adult
Provide Broadest Coverage Provide First and Only Conjugate
Vaccine That Offers Adults, Age
Available for the Global Protection
50 and Above, an Opportunity to
of Children Against Pneumococcal
Opportunity Prevent Pneumococcal
Disease
Pneumonia for the Rest of Their
Lives
Phase 2 Proof of Concept Proof of Concept Achieved
n n
Achieved
Licensing Criteria Agreed
n
Licensing Criteria Agreed Upon Upon
n
Status Worldwide Phase 3 Studies Worldwide Phase 3 Studies
n n
Ongoing Ongoing
Submission Early 2009 Submission Late 2009
n n
> $3 Billion > $1.5 Billion
Peak Sales
9

10. Growth Potential
Expanded Broad Spectrum Antibiotic That Can Simplify
n
Management of Patients at Risk of Resistance
4Over 250,000 Patients Treated Since Launch
Commercially Available in 46 Countries; 22 to Launch in 2008
n
Unmet Need Expanding With Growing Problem of Resistance
n
4MRSA Rates Now Exceed 50% in the U.S.
4Resistance to K.Pneumonia Exceed 23% in EU, AP and LA
Community-Acquired Pneumonia Submission Made in 3Q07;
n
Plan to Begin New Studies for Hospital-acquired Pneumonia
in 2008
$1B Peak Tygacil Sales
(Global)
10
MSRA Methicillin-resistant Staphylococcus Aureus

11. Growth Potential
Torisel Is the Only Renal Cell Carcinoma Agent Proven
n
to Extend Overall Survival
2nd Line Sutent Failures Currently Enrolling
n
4Data Available 2009
2nd Line RCC Represents ~50% of 2010 Sales
n
Phase III in Mantle Cell Lymphoma Complete – EU
n
Filing Anticipated Shortly
Torisel Peak Sales > $500M
(Global)
11

12. Wyeth Nutritionals Business Unit
Strong Revenue Growth in
n
International Markets $ Million
1,500
42006: Global Nutrition $1.2B
412% CAGR (’03-’06)
$1.1B
1,000
Business Based on Science
n
and Innovation
4Gold with Lutein 500
Compelling Product Line /
n
0
Markets 2003A 2004A 2005A 2006A 2007 9M
41st – 4th Age Segments Asia Pacific EMEA
Latin America N America
4Specialty Products
4Growing Markets
Source: Wyeth Finance
12

13. Wyeth Nutrition Global Presence
(YTD Sept 2007)
Europe /
Middle East
$275M
+ 16%
Asia Pacific
$609M
+ 19%
Latin America
$163M
+ 16%
YTD Sept 2007 Net Revenue
$1 Billion (+17%)
> 60 Countries
Notation: Region
Net Sales (YTD Sept 2007A) Growth, ’07 vs ’06
13
N America Sales not included

14. New Products Update

15. TM
Pristiq (desvenlafaxine): SNRI Refined
Therapy
DEPRESSION
FDA Approvable Letter Received; Action Date: Feb 2008
n
First Line Option for Treatment of Major Depressive Disorder
n
Excellent Results Achieved With Low Dose Studies
n
4 Demonstrated Efficacy at 50 mg; Replicated Efficacy at 100mg
4 Reduction in Adverse Event Related Discontinuation Rates vs. Higher Doses
4 Substantial Improvement in Nausea Rates and Overall Tolerability vs Higher Doses
VASOMOTOR SYMPTOMS
FDA Approvable Letter Received
n
Safety Study Under Discussion with FDA; Study Initiation Planned
n
for Early 2008
15

16. Methylnaltrexone:
Addressing a Significant Unmet Medical Need
Opioid Induced Constipation (OIC) Estimated 5 Million Patients With OIC
A Common Side Effect That Can Be a (U.S. Data)
n
Barrier to Effective Pain Management
Laxative Therapies Not Always
n
Effective
Arthritis/Joint
No Medicines Approved to Treat OIC
n
Advanced Illness
15%
Subcutaneous and Oral in Development 34%
n
PDUFA January 30, 2008 (SC)
n
All Neck/Back
37%
All Other
Post Operative Ileus (POI)
14%
A Complication of Surgery That Delays
n
Recovery and Can Extend Hospital Stay
No Medicines Approved to Treat POI
n
Potential for Significant Patient and
n
Economic Benefit ~ 1.8 Million Patients in Initial
NDA to Be Filed Mid 2008 Indication of Advanced Illness
n
Development collaboration with Progenics
16

17. Viviant™ for Osteoporosis
Prevention NDA Approvable Letter Issued April 23, 2007
n
4 FDA Requested Safety and Efficacy Data From the 3-Year Treatment Study
Including an Analysis of the Incidence of VTEs and Stroke
Complete Response Submitted June 2007
n
4 New FDA Action Date December 2007
Wyeth Evaluating Submission of Data From Two Additional
n
Clinical Studies to Be Completed in Late 2007 to Further Support
the Prevention Indication
NDA for Treatment of Osteoporosis Filed July 2007
n
Since Both NDAs Now Contain Virtually the Same Clinical Data It
n
Is Possible That the Timeline for the Review of These Two NDAs
May Move Closer Together
European Filing for Treatment and Prevention Completed in
n
September 2007
17

18. Aprela™ and Viviant™
Comprehensive Menopausal Therapy
TSEC SERM
Aprela Viviant
(Bazedoxifene/CE ) (Bazedoxifene)
Vasomotor Symptoms
Osteoporosis Prevention
Vulvovaginal Atrophy
Osteoporosis Treatment
Osteoporosis Prevention
18

19. ™
Aprela : First Tissue Selective Estrogen
Complex (TSEC) for Menopausal Women
Three Potential Indications:
4Treatment of Moderate to
Severe Vasomotor Symptoms
4Treatment of Moderate to
Severe Vulvar/Vaginal Atrophy
Target Filing Date:
4Prevention of Postmenopausal
U.S. 2Q 2008
Osteoporosis
Two Strengths:
420 mg/0.45mg Assumes Successful Completion
of Formulation and Bioequivalence
420mg/0.625mg
Work As Well As Clinical Studies
and Other Work Necessary for NDA
19

20. Positioning Wyeth To Be A Stronger
Company
Build Breadth and Diversity Into Every Aspect of the
n
Company So Wyeth Will Never Be Dependent on One
Product or Any One Research Program
Continue to Improve Profitability by Enhancing Productivity
n
Achieve Solid Top Line Growth, Effectively Manage Costs,
n
and Grow the Bottom Line at a Meaningfully Faster Rate
Than the Growth in Revenues
Position Wyeth to Be a Stronger Company at the End of
Position Wyeth to Be a Stronger Company at the End of
the Decade Then We Are Today and Enter the
the Decade Then We Are Today and Enter the
Next Decade With Great Momentum
Next Decade With Great Momentum
20